Skip to content
2000
Volume 25, Issue 7
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background: This study aimed to compare the efficacy and safety of PD-1/L1 inhibitors combined with anlotinib versus PD-1/L1 inhibitors combined with bevacizumab as second-line treatments for advanced NSCLC patients.

Methods

A retrospective analysis was carried out on data from advanced NSCLC patients who received either PD-1/L1 inhibitors combined with anlotinib or PD-1/L1 inhibitors combined with bevacizumab as second-line therapy. Clinical outcomes, including Overall Survival (OS), Progression-Free Survival (PFS), Objective Response Rate (ORR), Disease Control Rate (DCR), and Adverse Events (AEs), were compared between the two treatment groups.

Results

The results revealed that patients receiving PD-1/L1 inhibitors combined with anlotinib exhibited better efficacy compared to patients receiving PD-1/L1 inhibitors combined with bevacizumab (mPFS 5.0m vs. 4.0m, mOS 10.0m vs. 8.0m, ORR 31.25% vs. 17.14%, DCR 65.63% . 45.71%). Additionally, both treatment regimens were generally well-tolerated, with most adverse events being manageable and of mild to moderate severity. However, compared with patients receiving PD-1/L1 inhibitors combined with bevacizumab, those receiving PD-1/L1 inhibitors combined with anlotinib have higher incidence rates of certain adverse reactions (hypertension: 34.38% vs. 17.14%, proteinuria: 25% vs. 14.29%), implying that drug combinations of the same treatment modality may exhibit differences in efficacy and adverse reactions.

Conclusion

In this comparative study, PD-1/L1 inhibitors combined with anlotinib demonstrated superior efficacy compared to PD-1/L1 inhibitors combined with bevacizumab as second-line therapy for advanced NSCLC patients, with a manageable safety profile. These findings provide valuable clinical evidence for guiding treatment decisions in this patient population.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096338045241117161228
2025-01-16
2025-10-11

  • From This Site

    /content/journals/ccdt/10.2174/0115680096338045241117161228
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/ccdt/25/7/CCDT-25-7-13.html?itemId=/content/journals/ccdt/10.2174/0115680096338045241117161228&mimeType=html&fmt=ahah

References

  1. GantiA.K. KleinA.B. CotarlaI. SealB. ChouE. Update of incidence, prevalence, survival, and initial treatment in patients with non–small cell lung cancer in the US.JAMA Oncol.20217121824183210.1001/jamaoncol.2021.4932 34673888
     [Google Scholar]
  2. ChenP. LiuY. WenY. ZhouC. Non‐small cell lung cancer in China.Cancer Commun. (Lond.)2022421093797010.1002/cac2.12359 36075878
     [Google Scholar]
  3. DumaN. Santana-DavilaR. MolinaJ.R. Non–small cell lung cancer: Epidemiology, screening, diagnosis, and treatment.Mayo Clin. Proc.20199481623164010.1016/j.mayocp.2019.01.013 31378236
     [Google Scholar]
  4. AlduaisY. ZhangH. FanF. ChenJ. ChenB. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment.Medicine (Baltimore)20231028e3289910.1097/MD.0000000000032899 36827002
     [Google Scholar]
  5. AlexanderM. KimS.Y. ChengH. Update 2020: Management of Non-Small Cell Lung Cancer.Lung2020198689790710.1007/s00408‑020‑00407‑5 33175991
     [Google Scholar]
  6. MeloskyB. ChuQ. JuergensR. LeighlN. McLeodD. HirshV. Pointed progress in second-line advanced non–small-cell lung cancer: The rapidly evolving field of checkpoint Inhibition.J. Clin. Oncol.201634141676168810.1200/JCO.2015.63.8049 26884577
     [Google Scholar]
  7. ChenJ. AlduaisY. ChenB. Therapeutic and systemic adverse events of immune checkpoint inhibitors targeting the PD-1/PD-L1 axis for clinical management of NSCLC.Cell Transplant.2021300963689721104158710.1177/09636897211041587 34606729
     [Google Scholar]
  8. Eguren-SantamariaI. SanmamedM.F. GoldbergS.B. KlugerH.M. IdoateM.A. LuB.Y. CorralJ. SchalperK.A. HerbstR.S. Gil-BazoI. PD-1/PD-L1 blockers in NSCLC brain metastases: Challenging paradigms and clinical practice.Clin. Cancer Res.202026164186419710.1158/1078‑0432.CCR‑20‑0798 32354698
     [Google Scholar]
  9. GarassinoM.C. GadgeelS. SperanzaG. FelipE. EstebanE. DómineM. HochmairM.J. PowellS.F. BischoffH.G. PeledN. GrossiF. JennensR.R. ReckM. HuiR. GaronE.B. KurataT. GrayJ.E. SchwarzenbergerP. JensenE. PietanzaM.C. Rodríguez-AbreuD. Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study.J. Clin. Oncol.202341111992199810.1200/JCO.22.01989 36809080
     [Google Scholar]
  10. BrahmerJ.R. LeeJ.S. CiuleanuT.E. Bernabe CaroR. NishioM. UrbanL. Audigier-ValetteC. LupinacciL. SanghaR. PluzanskiA. BurgersJ. MahaveM. AhmedS. SchoenfeldA.J. Paz-AresL.G. ReckM. BorghaeiH. O’ByrneK.J. GuptaR.G. BushongJ. LiL. BlumS.I. EcclesL.J. RamalingamS.S. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227.J. Clin. Oncol.20234161200121210.1200/JCO.22.01503 36223558
     [Google Scholar]
  11. TangQ. ChenY. LiX. LongS. ShiY. YuY. WuW. HanL. WangS. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.Front. Immunol.20221396444210.3389/fimmu.2022.964442 36177034
     [Google Scholar]
  12. RicciutiB. LambertiG. PuchalaS.R. MahadevanN.R. LinJ.R. AlessiJ.V. ChowdhuryA. LiY.Y. WangX. SpurrL. PecciF. Di FedericoA. VenkatramanD. BarrichelloA.P. GandhiM. VazV.R. PangilinanA.J. HaradonD. LeeE. GuptaH. PfaffK.L. WelshE.L. NishinoM. CherniackA.D. JohnsonB.E. WeiratherJ.L. DrygI.D. RodigS.J. ShollL.M. SorgerP. SantagataS. UmetonR. AwadM.M. Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer.J. Clin. Oncol.202442111311132110.1200/JCO.23.00580 38207230
     [Google Scholar]
  13. BorghaeiH. CiuleanuT.E. LeeJ.S. PluzanskiA. CaroR.B. GutierrezM. OheY. NishioM. GoldmanJ. ReadyN. SpigelD.R. RamalingamS.S. Paz-AresL.G. GainorJ.F. AhmedS. ReckM. MaioM. O’ByrneK.J. MemajA. NathanF. TranP. HellmannM.D. BrahmerJ.R. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: A pooled analysis.Ann. Oncol.202334217318510.1016/j.annonc.2022.11.006 36414192
     [Google Scholar]
  14. MakharadzeT. GogishviliM. MelkadzeT. BaramidzeA. GiorgadzeD. PenkovK. LaktionovK. NemsadzeG. NechaevaM. RozhkovaI. KalinkaE. LiS. LiY. KaulM. QuekR.G.W. PouliotJ.F. SeebachF. LowyI. GulloG. RietschelP. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-lung 3 part 2 trial.J. Thorac. Oncol.202318675576810.1016/j.jtho.2023.03.008 37001859
     [Google Scholar]
  15. NovelloS. KowalskiD.M. LuftA. GümüşM. VicenteD. MazièresJ. Rodríguez-CidJ. TafreshiA. ChengY. LeeK.H. GolfA. SugawaraS. RobinsonA.G. HalmosB. JensenE. SchwarzenbergerP. PietanzaM.C. Paz-AresL. Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study.J. Clin. Oncol.202341111999200610.1200/JCO.22.01990 36735893
     [Google Scholar]
  16. QiangH. ChangQ. XuJ. QianJ. ZhangY. LeiY. HanB. ChuT. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.J. Cancer Res. Clin. Oncol.2020146363164510.1007/s00432‑020‑03129‑6 32065262
     [Google Scholar]
  17. GlorieuxC. XiaX. YouX. WangZ. HanY. YangJ. NoppeG. MeesterC. LingJ. RobertA. ZhangH. LiS.P. WangH. ChiaoP.J. ZhangL. LiX. HuangP. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.J. Adv. Res.20224010912410.1016/j.jare.2021.12.005 36100320
     [Google Scholar]
  18. YinC. ZouG.R. HeY. LiJ. YanH.W. SuZ. CaoX.L. LiX.B. Efficiency and toxicity of nab-paclitaxel and camrelizumab in the second or above line treatment of advanced non-small cell lung cancer: A retrospective cohort study.J. Thorac. Dis.20231541838184710.21037/jtd‑23‑387 37197501
     [Google Scholar]
  19. ShiraishiY. KishimotoJ. SugawaraS. MizutaniH. DagaH. AzumaK. MatsumotoH. HatajiO. NishinoK. MoriM. ShukuyaT. SaitoH. TachiharaM. HayashiH. TsuyaA. WakudaK. YanagitaniN. SakamotoT. MiuraS. HataA. OkadaM. KozukiT. SatoY. HaradaT. TakayamaK. YamamotoN. NakagawaK. OkamotoI. Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non–small cell lung cancer.JAMA Oncol.202410331532410.1001/jamaoncol.2023.5258 38127362
     [Google Scholar]
  20. LuS. WuL. JianH. ChengY. WangQ. FangJ. WangZ. HuY. HanL. SunM. MiaoL. DingC. CuiJ. WangK. LiB. LiX. YeF. LiuA. PanY. CangS. ZhouH. SunX. ShenY. WangS. ZhangW. HeY. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Respir. Med.202311762463610.1016/S2213‑2600(23)00135‑2 37156249
     [Google Scholar]
  21. ZhangX. ZengL. LiY. XuQ. YangH. LizasoA. MaoX. JinR. ZengY. LiQ. WangJ. LiY. ZhangY. YangN. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: A real-world retrospective study in China.Cancer Immunol. Immunother.20217092517252810.1007/s00262‑021‑02869‑9 33566148
     [Google Scholar]
  22. YuC. JiangL. YangD. DongX. YuR. YuH. Anlotinib hydrochloride and PD-1 blockade as a salvage second-line treatment in patients with progress of local advanced non-small cell lung cancer in half a year after standard treatment.OncoTargets Ther.2022151221122810.2147/OTT.S380615 36262804
     [Google Scholar]
  23. LiS. WangH. Research progress on mechanism and management of adverse drug reactions of anlotinib.Drug Des. Devel. Ther.2023173429343710.2147/DDDT.S426898 38024530
     [Google Scholar]
  24. HanB. LiK. ZhaoY. LiB. ChengY. ZhouJ. LuY. ShiY. WangZ. JiangL. LuoY. ZhangY. HuangC. LiQ. WuG. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: A multicentre, randomised phase II trial (ALTER0302).Br. J. Cancer2018118565466110.1038/bjc.2017.478 29438373
     [Google Scholar]
  25. SyedY.Y. Anlotinib: First global approval.Drugs201878101057106210.1007/s40265‑018‑0939‑x 29943374
     [Google Scholar]
  26. SiX. ZhangL. WangH. ZhangX. WangM. HanB. LiK. WangQ. ShiJ. WangZ. ChengY. HeJ. ShiY. ChenW. WangX. LuoY. NanK. JinF. LiB. ChenY. ZhouJ. WangD. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.Lung Cancer2018122323710.1016/j.lungcan.2018.05.013 30032842
     [Google Scholar]
  27. LiX. PengY. WuD. TangJ. WuY. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy.J. Chemother.20241910.1080/1120009X.2024.2397924 39219263
     [Google Scholar]
  28. GerrietsV. KasiA. Bevacizumab.In: StatPearls.Treasure Island, FLStatPearls Publishing2024
     [Google Scholar]
  29. AschaM.S. WangJ.F. KumthekarP. SloanA.E. KruchkoC. Barnholtz-SloanJ.S. Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases.Sci. Rep.2019911779210.1038/s41598‑019‑54513‑3 31780762
     [Google Scholar]
  30. BarlesiF. ScherpereelA. RittmeyerA. PazzolaA. Ferrer TurN. KimJ.H. AhnM.J. AertsJ.G.J.V. GorbunovaV. VikströmA. WongE.K. Perez-MorenoP. MitchellL. GroenH.J.M. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).J. Clin. Oncol.201331243004301110.1200/JCO.2012.42.3749 23835708
     [Google Scholar]
  31. ZhouC. WuY.L. ChenG. LiuX. ZhuY. LuS. FengJ. HeJ. HanB. WangJ. JiangG. HuC. ZhangH. ChengG. SongX. LuY. PanH. ZhengW. YinA.Y. BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non–small-cell lung cancer.J. Clin. Oncol.201533192197220410.1200/JCO.2014.59.4424 26014294
     [Google Scholar]
  32. TangH. YouT. GeH. GaoJ. WangY. BaiC. SunZ. HanQ. ZhaoR.C. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.Int. Immunopharmacol.202413311205310.1016/j.intimp.2024.112053 38615380
     [Google Scholar]
  33. ZhouN. JiangM. LiT. ZhuJ. LiuK. HouH. ZhangX. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study.Lung Cancer202116011111710.1016/j.lungcan.2021.08.006 34482102
     [Google Scholar]
  34. SunL. ZhaoQ. WangY. WangY. ZhengM. DingX. MiaoL. Efficacy and safety of anlotinib-containing regimens in advanced non-small cell lung cancer: A real-world study.Int. J. Gen. Med.2023164165417910.2147/IJGM.S424777 37720175
     [Google Scholar]
  35. XiongQ. QinB. XinL. YangB. SongQ. WangY. ZhangS. HuY. Real-world efficacy and safety of anlotinib with and without immunotherapy in advanced non-small cell lung cancer.Front. Oncol.20211165938010.3389/fonc.2021.659380 34395243
     [Google Scholar]
  36. ChuT. ZhongR. ZhongH. ZhangB. ZhangW. ShiC. QianJ. ZhangY. ChangQ. ZhangX. DongY. TengJ. GaoZ. QiangH. NieW. ZhaoY. HanY. ChenY. HanB. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC.J. Thorac. Oncol.202116464365210.1016/j.jtho.2020.11.026 33524601
     [Google Scholar]
  37. ChuT. ZhangW. ZhangB. ZhongR. ZhangX. GuA. ShiC. WangH. XiongL. LuJ. QianJ. ZhangY. DongY. TengJ. GaoZ. WangW. ShenY. NieW. LimJ.U. MehtaH.J. NealJ.W. LouY. XuJ. ZhongH. HanB. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: A three-armed prospective study.Transl. Lung Cancer Res.20221171394140410.21037/tlcr‑22‑438 35958322
     [Google Scholar]
  38. LiuY. ZhangT. ZhangL. ZhaoC. ZhangZ. WangZ. GuM. LiW. LiB. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+ T cells in lung cancer.Immunotherapy202214969570810.2217/imt‑2021‑0196 35574588
     [Google Scholar]
  39. DansinÉ. CousinS. LauridantG. MennecierB. [Bevacizumab in thoracic oncology: Results and practical aspects]Rev. Pneumol. Clin.201369315916910.1016/j.pneumo.2013.02.006 23597632
     [Google Scholar]
  40. SooR.A. HanJ.Y. DafniU. ChoB.C. YeoC.M. NadalE. CarcerenyE. de CastroJ. SalaM.A. BernabéR. CoateL. Provencio PullaM. Garcia CampeloR. CuffeS. HashemiS.M.S. FrühM. MassutiB. Garcia-SanchezJ. DómineM. MajemM. Sanchez-TorresJ.M. BritschgiC. PlessM. DimopoulouG. Roschitzki-VoserH. RueppB. RosellR. StahelR.A. PetersS. StahelR. PetersS. SooR. HanJ-Y. FrühM. ProvencioM. CoateL. DafniU. HiltbrunnerA. RueppB. Roschitzki-VoserH. HiltbrunnerA. Gasca-RuchtiA. GiacomelliN. KammlerR. MartiN. NobsL. Pardo-ContrerasM. PfisterR. PiguetA-C. Ribeli-HofmannS. MartinezV.R. Roschitzki-VoserH. RouxS. RueppB. Sanchez-HohlM. SchneiderM. SchweriR. TroeschS. ZigomoI. DafniU. TsourtiZ. ZygouraP. KassapianM. VervitaK. DimopoulouG. AndriakopoulouC. FernandezM. PereiraE. SimonaC. TuckerL. BurnesJ. BarrettA. McGrillenM. BersetC. BiaggiC. ReistM. RentschP. CoateL. CuffeS. HashemiS. NadalE. CarcerenyE. de CastroJ. SalaM.A. ReyesB. PullaM.P. CampeloR.G. MassutíB. GarciaJ. DómineM. MajemM. SanchezJ.M. FrühM. BritschgiC. PlessM. PetersS. SooR. YeoC.M. HanJ-Y. ChoB.C. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: The European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.Ann. Oncol.202233218119210.1016/j.annonc.2021.11.010 34839016
     [Google Scholar]
  41. SaitoH. FukuharaT. FuruyaN. WatanabeK. SugawaraS. IwasawaS. TsunezukaY. YamaguchiO. OkadaM. YoshimoriK. NakachiI. GemmaA. AzumaK. KurimotoF. TsubataY. FujitaY. NagashimaH. AsaiG. WatanabeS. MiyazakiM. HagiwaraK. NukiwaT. MoritaS. KobayashiK. MaemondoM. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): Interim analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol.201920562563510.1016/S1470‑2045(19)30035‑X 30975627
     [Google Scholar]
  42. GerberD.E. HornL. BoyerM. SanbornR. NataleR. PalmeroR. BidoliP. BondarenkoI. GermonpreP. GhizdavescuD. KotsakisA. LenaH. LosonczyG. ParkK. SuW.C. TangM. LaiJ. KallinterisN.L. ShanJ.S. ReckM. SpigelD.R. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.Ann. Oncol.20182971548155310.1093/annonc/mdy177 29767677
     [Google Scholar]
  43. ReckM. PopatS. GrohéC. CorralJ. NovelloS. GottfriedM. BruecklW. RadonjicD. KaiserR. HeymachJ. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives.Lung Cancer202317910717310.1016/j.lungcan.2023.03.009 36940614
     [Google Scholar]
  44. MederL. SchuldtP. ThelenM. SchmittA. DietleinF. KleinS. BorchmannS. WennholdK. VlasicI. OberbeckS. RiedelR. FlorinA. GolfmannK. SchlößerH.A. OdenthalM. BuettnerR. WolfJ. HallekM. HerlingM. von Bergwelt-BaildonM. ReinhardtH.C. UllrichR.T. Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer.Cancer Res.201878154270428110.1158/0008‑5472.CAN‑17‑2176 29776963
     [Google Scholar]
  45. JohnsonP.C. GainorJ.F. SullivanR.J. LongoD.L. ChabnerB. Immune checkpoint inhibitors - The need for innovation.N. Engl. J. Med.2023388161529153210.1056/NEJMsb2300232 37075146
     [Google Scholar]
  46. XiaL. LiuY. WangY. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: Current status and future directions.Oncologist201924Suppl. 1S31S4110.1634/theoncologist.2019‑IO‑S1‑s05 30819829
     [Google Scholar]
  47. LiX. WuD. TangJ. WuY. The efficiency and safety of triple-drug combination of albumin-bound paclitaxel, anlotinib and PD-1/L1 inhibitors in the 2nd or above line of advanced NSCLC: A retrospective cohort study.Cancer Manag. Res.2024161003101210.2147/CMAR.S472196 39135711
     [Google Scholar]
  48. LiX. WuD. TangJ. WuY. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: A retrospective cohort.J. Cancer Res. Clin. Oncol.2024150527110.1007/s00432‑024‑05808‑0 38780840
     [Google Scholar]
  49. TangJ. JiangH. XiangZ. ZhuX. XieR. WuD. PengL. LiX. Apatinib plus docetaxel or pemetrexed shows promising activities against non-small cell lung cancer with brain metastasis: A retrospective analysis.J. Thorac. Dis.202416161562210.21037/jtd‑23‑1860 38410538
     [Google Scholar]
  50. KhanK.A. KerbelR.S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.Nat. Rev. Clin. Oncol.201815531032410.1038/nrclinonc.2018.9 29434333
     [Google Scholar]
  51. FukumuraD. KloepperJ. AmoozgarZ. DudaD.G. JainR.K. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges.Nat. Rev. Clin. Oncol.201815532534010.1038/nrclinonc.2018.29 29508855
     [Google Scholar]
  52. PaddaS.K. ReckampK.L. Combination of immunotherapy and antiangiogenic therapy in cancer - A rational approach.J. Thorac. Oncol.202116217818210.1016/j.jtho.2020.11.007 33494922
     [Google Scholar]
  53. CabebeE. WakeleeH. Role of anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors.Curr. Treat. Options Oncol.200781152710.1007/s11864‑007‑0022‑4 17634832
     [Google Scholar]
  54. ZhouC. WangY. ZhaoJ. ChenG. LiuZ. GuK. HuangM. HeJ. ChenJ. MaZ. FengJ. ShiJ. YuX. ChengY. YaoY. ChenY. GuoR. LinX. WangZ. GaoG. WangQ. LiW. YangX. WuL. ZhangJ. RenS. Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy.Clin. Cancer Res.20212751296130410.1158/1078‑0432.CCR‑20‑3136 33323401
     [Google Scholar]
  55. TangJ. LiX.Y. LiangJ.B. WuD. PengL. LiX. Apatinib plus chemotherapy shows clinical activity in advanced NSCLC: A retrospective study.Oncol. Res.201927663564110.3727/096504018X15288447760357 29929572
     [Google Scholar]
  56. BorghaeiH. GettingerS. VokesE.E. ChowL.Q.M. BurgioM.A. de Castro CarpenoJ. PluzanskiA. ArrietaO. FronteraO.A. ChiariR. ButtsC. Wójcik-TomaszewskaJ. CoudertB. GarassinoM.C. ReadyN. FelipE. GarcíaM.A. WaterhouseD. DomineM. BarlesiF. AntoniaS. WohlleberM. GerberD.E. CzyzewiczG. SpigelD.R. CrinoL. EberhardtW.E.E. LiA. MarimuthuS. BrahmerJ. Five-year outcomes from the randomized, phase iii trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non–small-cell lung cancer.J. Clin. Oncol.202139772373310.1200/JCO.20.01605 33449799
     [Google Scholar]
  57. GaronE.B. HellmannM.D. RizviN.A. CarcerenyE. LeighlN.B. AhnM.J. EderJ.P. BalmanoukianA.S. AggarwalC. HornL. PatnaikA. GubensM. RamalingamS.S. FelipE. GoldmanJ.W. ScalzoC. JensenE. KushD.A. HuiR. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 study.J. Clin. Oncol.201937282518252710.1200/JCO.19.00934 31154919
     [Google Scholar]
  58. QiuL. ZhaoX. ShiW. SunS. ZhangG. SunQ. MengJ. XiongQ. QinB. JiaoS. Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients.Medicine (Baltimore)20209924e2054510.1097/MD.0000000000020545 32541476
     [Google Scholar]
  59. TaylorM.H. LeeC.H. MakkerV. RascoD. DutcusC.E. WuJ. StepanD.E. ShumakerR.C. MotzerR.J. Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors.J. Clin. Oncol.202038111154116310.1200/JCO.19.01598 31961766
     [Google Scholar]
  60. WangP. FangX. YinT. TianH. YuJ. TengF. Efficacy and safety of anti-pd-1 plus anlotinib in patients with advanced non–small-cell lung cancer after previous systemic treatment failure - A retrospective study.Front. Oncol.20211162812410.3389/fonc.2021.628124 33791214
     [Google Scholar]
  61. LiangL. HuiK. HuC. WenY. YangS. ZhuP. WangL. XiaY. QiaoY. SunW. FeiJ. ChenT. ZhaoF. YangB. JiangX. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.J. Exp. Clin. Cancer Res.20193817110.1186/s13046‑019‑1093‑3 30755242
     [Google Scholar]
  62. WenfanF. ManmanX. XingyuanS. ZeyongJ. JianZ. LuD. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: A systematic review and Bayesian network meta-analysis.Ther. Adv. Chronic Dis.2023142040622323118922410.1177/20406223231189224 37841212
     [Google Scholar]
  63. ChenJ. LiuX. ZhangJ. HuangZ. ZengW. HuJ. ChenG. GongY. LiuY. XieC. Frontline anti-PD-1/PD-L1 versus bevacizumab in advanced non-small-cell lung cancer: A network meta-analysis.Future Oncol.202218131651166410.2217/fon‑2021‑0838 35129371
     [Google Scholar]
  64. LeeJ. KohJ. KimH.K. HongS. KimK. ParkS. JungH.A. SunJ.M. LeeS.H. AhnJ.S. ParkK. AhnM.J. Bevacizumab plus atezolizumab after progression on atezolizumab monotherapy in pretreated patients with NSCLC: An open-label, two-stage, phase 2 trial.J. Thorac. Oncol.202217790090810.1016/j.jtho.2022.04.001 35427805
     [Google Scholar]
  65. LiW. ZhouC. YuL. HouZ. LiuH. KongL. XuY. HeJ. LanJ. OuQ. FangY. LuZ. WuX. PanZ. PengJ. LinJ. Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer.Autophagy202420111413010.1080/15548627.2023.2249762 37615625
     [Google Scholar]
  66. ChenC. WangZ. DingY. QinY. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma.Front. Immunol.202314113330810.3389/fimmu.2023.1133308 36845131
     [Google Scholar]
  67. ZhangF. HuangD. LiT. ZhangS. WangJ. ZhangY. WangG. ZhaoZ. MaJ. WangL. SunD. CuiP. CaiS. JiaoS. ZhaoL. HuY. Anti-PD-1 therapy plus chemotherapy and/or bevacizumab as second line or later treatment for patients with advanced non-small cell lung cancer.J. Cancer202011374174910.7150/jca.37966 31942197
     [Google Scholar]
  68. YeX. HuangA. ZhouY. KuangY. WangW. GuA. XuL. Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: A retrospective cohort study.J. Thorac. Dis.20231542003201110.21037/jtd‑23‑289 37197506
     [Google Scholar]
  69. YuL. XuJ. QiaoR. HanB. ZhongH. ZhongR. Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer.Cancer Med.20231255372538310.1002/cam4.5360 36250532
     [Google Scholar]
  70. ZhaiC. ZhangX. RenL. YouL. PanQ. PanH. HanW. The efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer.Front. Oncol.20211061901010.3389/fonc.2020.619010 33680942
     [Google Scholar]
  71. SiX. ZhangL. WangH. ZhangX. WangM. HanB. LiK. WangQ. ShiJ. WangZ. ChengY. ShiY. ChenW. WangX. LuoY. NanK. JinF. Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303.Thorac. Cancer201910355155610.1111/1759‑7714.12977 30666799
     [Google Scholar]
  72. ChengY. ChenJ. ZhangW. XieC. HuQ. ZhouN. HuangC. WeiS. SunH. LiX. YuY. LaiJ. YangH. FangH. ChenH. ZhangP. GuK. WangQ. ShiJ. YiT. XuX. YeX. WangD. XieC. LiuC. ZhengY. LinD. ZhuangW. LuP. YuG. LiJ. GuY. LiB. WuR. JiangO. WangZ. WuG. LinH. ZhongD. XuY. ShuY. WuD. ChenX. WangJ. WangM. YangR. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: A randomized phase 3 trial.Nat. Med.202430102967297610.1038/s41591‑024‑03132‑1 38992123
     [Google Scholar]
  73. BaschE. WoodW.A. SchragD. SimaC.S. ShawM. RogakL.J. KrisM.G. ShoueryM. BennettA. AtkinsonT. PietanzaM.C. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial.Clin. Trials201613333133710.1177/1740774515615540 26542025
     [Google Scholar]
  74. HirshV. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.Clin. Lung Cancer20089Suppl. 2S62S7010.3816/CLC.2008.s.010 21885001
     [Google Scholar]
  75. GuT. JiangA. ZhouC. LinA. ChengQ. LiuZ. ZhangJ. LuoP. Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis.Int. J. Cancer2023152348049510.1002/ijc.34332 36274626
     [Google Scholar]
  76. ChenK. XuY. HuangZ. YuX. HongW. LiH. XuX. LuH. XieF. ChenJ. XuY. FanY. Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial.Cancer Med.20231219194601947010.1002/cam4.6548 37723837
     [Google Scholar]
  77. DouX.J. MaR.Y. RenD.W. LiuQ. YanP. Effectiveness and safety of anlotinib combined with PD-1 blockades in patients with previously immunotherapy treated advanced non-small cell lung cancer: A retrospective exploratory study.Lung Cancer (Auckl.)202415294010.2147/LCTT.S444884 38560413
     [Google Scholar]
  78. ChenB. YaoW. LiX. LinG. ChuQ. LiuH. DuY. LinJ. DuanH. WangH. XiaoZ. SunH. LiuL. XuL. XuY. XuF. KongY. PuX. LiK. WangQ. LiJ. LiB. XiaY. WuL. A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.Br. J. Cancer2024130345045610.1038/s41416‑023‑02519‑0 38110665
     [Google Scholar]
/content/journals/ccdt/10.2174/0115680096338045241117161228
Loading
Efficacy and Safety of PD-1/L1 Inhibitors Combined with Anlotinib versus PD-1/L1 Inhibitors Combined with Bevacizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients: A Comparative Cohort Study
Curr. Cancer Drug Targets< 25, 855 (2025); https://doi.org/10.2174/0115680096338045241117161228
/content/journals/ccdt/10.2174/0115680096338045241117161228
/content/journals/ccdt/10.2174/0115680096338045241117161228
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): anlotinib; bevacizumab; PD-1/L1 inhibitors; treatment,NSCLC

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test